Consensus and controversy in pharmaceutical statistics

Journal of the Royal Statistical Society Series D: The Statistician

Volumn 49, Issue 2, 2000, Pages 135-176

  Senn, Stephen ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Bayesian inference; Bioequivalence; Cross over trials; Frequentist inference; Model checking; Multiplicity; Randomization; Sequential trials

Indexed keywords

EID: 0347807759     PISSN: 00390526     EISSN: None     Source Type: Journal    
DOI: 10.1111/1467-9884.00227     Document Type: Article

References (50)

1. Ashby, D. and Smith, A. F. M. (2000) Evidence based medicine as Bayesian decision-making. Statist. Med., to be published.
2. Atkinson, A. C. (1999a) Optimum biased-coin designs for sequential treatment allocation with covariate information. Statist. Med., 18, 1741-1756.
3. _(1999b) The comparison of designs for sequential clinical trials with covariate information. To be published.
4. _(1999c) Bayesian and other biased-coin designs for sequential clinical trials. Tatra Mt Math. Publ., 17, 133-139.
5. Ball, F. G., Smith, A. F. M. and Verdinelli, I. (1993) Biased coin designs with a Bayesian bias. J. Statist. Planng Inf., 34, 403-421.
6. Barnard, G. (1966) Fragments of a statistical autobiography. Student, 1, 257-268.
7. Berger, J. O. and Sellke, T. (1987) Testing a point null hypothesis: the irreconcilability of P values and evidence. J. Am. Statist. Ass., 82, 112-139.
8. Campbell, G. (1999) A Regulatory Perspective for Bayesian Clinical Trials. Rockville: Food and Drug Administration. (Available from http://www.fda.gov/cdrh/present/bayesian.pdf.)
9. Claxton, K. (1999) Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. Hlth Econ., 8, 269-274.
10. Draper, N. R. and Smith, H. (1998) Applied Regression Methods, 3rd edn. New York: Wiley.
11. Ebbutt, A. (1998) The analysis of trials where treatment allocation uses a minimisation algorithm. In 20th Anniversary Conf. Annual General Meet., Sept. 7th-10th, 1997, programme and abstracts, p. 26. Macclesfield: PSI.
12. Einstein, A., Podolsky, P. and Rosen, N. (1935) Can quantum-mechanical description of physical reality be considered complete? Phys. Rev., 47, 777-780.
13. European Federation of Statisticians in the Pharmaceutical Industry (1999) Qualified statisticians in the European pharmaceutical industry: report of an EFSPI working group. Drug Inform. J., 33, 407-415.
14. Evans, S. J. W. (2000) Pharmacovigilance; a science or fielding emergencies. Statist. Med., 19, in the press.
15. de Finetti, B. (1990) Theory of Probability (Engl. transl. A. Machi and A. Smith). Chichester: Wiley.
16. Food and Drug Administration (1998a) Semiannual guidance agenda. Fed. Reg., 63, 59317-59326.
17. _(1998b) Cardiovascular and Renal Drugs Advisory Committee Meet., June 26th, 1997, transcript. Rockville: Food and Drug Administration. (Available from http://www.fda.gov/ohrms/dockets/ac/97/transcpt/ 3320t1.pdf.)
18. _(1999) Summary of Safety and Effectiveness Data for T-scan Breast Scanner. Rockville: Food and Drug Administration. (Available from http://www.fda.gov/cdrh/pdf/p970033b.pdf.)
19. Frane, J. W. (1998) A method of biased coin randomization, its implementation, and its validation. Drug Inform. J., 32, 423-432.
20. Freeman, P. R. (1989) The performance of the two-stage analysis of two-treatment, two-period cross-over trials. Statist. Med., 8, 1421-1432.
21. Good, J. (1983) Good Thinking. Minneapolis: University of Minnesota Press.
22. Goodman, N. (1992) A comment on replication, P-values and evidence. Statist. Med., 11, 875-879.
23. Grieve, A. P. and Senn, S. J. (1998) Estimating treatment effects in clinical crossover trials. J. Biopharm. Statist., 8, 191-233.
24. Holmgren, E. B. (1999) Establishing equivalence by showing that a specified percentage of the effect of active control over placebo is maintained. J. Biopharm. Statist., 9, 651-659.
25. ICH E9 Expert Working Group (1999) Statistical principles for clinical trials: ICH harmonised tripartite guidelines. Statist. Med., 18, 1905-1942.
26. Keiding, N. (1994) Discussion on 'Bayesian approaches to randomized trials' (by D. J. Spiegelhalter, L. S. Freedman and M. K. B. Parmar). J. R. Statist. Soc. A, 157, 395.
27. Koch, G. G. (1991) Summary and discussion for 'Statistical issues in the pharmaceutical industry: analysis and reporting of phase III clinical trials including kinetic/dynamic analysis and Bayesian analysis'. Drug Inform. J., 25, 433-437.
28. Koch, G. G., Davis, S. M. and Anderson, R. L. (1998) Methodological advances and plans for improving regulatory success for confirmatory studies. Statist. Med., 17, 1675-1690.
29. Kremers, W. (1999) Some statistical issues of clinical trials with large number of small centers. Internal Document. Novartis, Basle.
30. Lehmann, E. L. (1993) The Fisher, Neyman-Pearson theories of testing hypotheses: one theory or two? J. Am. Statist. Ass., 88, 1242-1249.
31. Lewis, J. A. (1983) Clinical trials: statistical developments of practical benefit to the pharmaceutical industry (with discussion). J. R. Statist. Soc. A, 146, 362-393.
32. _(1999) Statistical principles for clinical trials: an introductory note on an international guideline. Statist. Med., 18, 1903-1904.
33. Lindsay, R. M. and Ehrenberg, A. S. C. (1993) The design of replicated studies. Am. Statistn, 47, 217-228.
34. Longford, N. T. (1999) Selection bias and treatment heterogeneity in clinical trials. Statist. Med., 18, 1467-1474.
35. _(2000) Synthetic estimation with moderating influence: carryover in crossover trials revisited. To be published.
36. Matthews, R. (1998) Fact versus factions: the use and abuse of subjectivity in scientific research. Technical Report. European Science and Environment Forum, Cambridge.
37. O'Neill, R. T. (1994a) Conclusions: 2. Statist. Med., 13, 1493-1499.
38. _(1994b) Statistical analysis of clinical data. In International Pharmaceutical Product Registration: Aspects of Quality, Safety and Efficacy (eds A. C. Cartwright and B. R. Matthews), ch. 22. London: Taylor and Francis.
39. Ottenbacher, K. J. (1996) The power of replications and replications of power. Am. Statistn, 50, 272-275.
40. Patel, H. I. (1983) The use of baseline measurements in a two-period cross-over design with reference to clinical trials. Communs Statist. Theory Meth., 12, 2693-2712.
41. Phillips, A., Ebbutt, A., France, L. and Morgan, D. (2000) ICH guideline "Statistical Principles for Clinical Trials": issues in applying the guideline in practice. Drug Inform. J., 34, in the press.
42. Racine, A., Grieve, A. P., Flühler, H. and Smith, A. F. M. (1986) Bayesian methods in practice: experiences in the pharmaceutical industry (with discussion). Appl. Statist., 35, 93-150.
43. Schall, R. and Luus, H. G. (1993) On population and individual bioequivalence. Statist. Med., 12, 1109-1124.
44. Senn, S. J. (1993) Cross-over Trials in Clinical Research. Chichester: Wiley.
45. _(1997) Statistical Issues in Drug Development. Chichester: Wiley.
46. _(1998) In the blood. Lancet, 352, 85-86.
47. Spiegelhalter, D. J., Thomas, A., Best, N. G. and Gilks, W. R. (1996) BUGS: Bayesian Inference using Gibbs Sampling, Version 0.5, (Version ii). Cambridge: Medical Research Council Biostatistics Unit.
48. Staquet, S., Rozencweig, M., VonHoff, D. D. and Muggia, F. M. (1979) The delta and epsilon errors in the assessment of cancer clinical trials. Cancer Treatmnt Rep., 63, 1917-1921.
49. Westfall, P. H., Krishen, A. and Young, S. S. (1997) Using prior information to allocate significance levels for multiple endpoints. Statist. Med., 17, 2107-2119.
50. Whitehead, J. (1997) The Design and Analysis of Sequential Clinical Trials, 2nd edn. Chichester: Wiley.